Pfizer expects to collect 100 billion USD in 2022
Pfizer expects to collect 100 billion USD in 2022 Pfizer's revenue is forecast to grow strongly this year, with Covid-19 vaccines and drugs contributing more than half. The US pharmaceutical company said that soaring sales of Covid-19 drugs and vaccines will continue to push the company's revenue in 2022 to $ 100 billion. In which, sales of antiviral drug Paxlovid will reach about 22 billion USD, and vaccine will reach 32 billion USD. Last year, Paxlovid brought in $76 million, while the vaccine was $36.8 billion. Pfizer has made a number of recent acquisitions and partnerships to strengthen its ability to deliver drugs and vaccines. In December 2021, Pfizer said it would buy Arena Pharmaceuticals for $6.7 billion. The company has also invested $25 billion in business development since 2019. Pfizer headquarters in New York, USA. Photo: Bloomberg Pfizer headquarters in New York, USA. Photo: Bloomberg With growing cash on hand, Pfizer said its acquisition strategy will focus on ...